Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Commercial and Pipeline Insight - Systemic antifungals

Commercial and Pipeline Insight - Systemic antifungals

"IntroductionThe systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.ScopeIn-depth analysis of the market for systemic antifungals covering Japan, US, France, Italy, Germany, Spain and the UK Product by product analysis of the key marketed and pipeline brands that will determine the market’s evolution An assessment of key unmet needs and the opportunities they offer for new product development Key considerations for trial design as pre-emptive and targeted strategies replace prophylactic and empiric strategiesHighlightsOver the 2002 to 2006 period, the market for systemic antifungals has risen by a moderate 3.3% from $2.7billion to $3.1 billion; however, its value has dropped by 7.4% between 2005 and 2006. The US and M5EU launch of the next wave of echinocandins (Eraxis and Mycamine) and the next generation azoles (Vfend and Noxafil) will shorten the current period of devaluation of the market caused by widespread uptake of generic fluconazole and itraconazole. New diagnostic technology promises to offer clinicians far better decision making tools, emphasizing the need for a rethink of antifungal clinical trial design. Innovative approaches will be needed to ensure that already costly trials do not become prohibitively expensive, while remaining clinically relevant. Reasons to PurchaseUnderstand clinical and commercial impact of key marketed and pipeline products on the future shape of the systemic fungal infections market Understand the key clinical analysis that will be essential to cater to clinicians’ information needs and gain widespread use Review the impacts of new diagnostic techniques on antifungal treatment strategies"

14-Nov-07 Format: PDF & SlidePack & DataPack Pages: 393
Table of Contents
Price: $15,200.00 / €10,168.80

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions